Psychotic Disorders - Benelux | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$183.70m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.31%, resulting in a market volume of US$186.60m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$473.50 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in Benelux is experiencing steady growth due to a combination of customer preferences, market trends, local special circumstances, and underlying macroeconomic factors.Customer preferences in the Psychotic Disorders market in Benelux are driving the demand for innovative treatment options and personalized care. Patients are increasingly seeking treatments that not only alleviate symptoms but also improve their overall quality of life. This has led to a rise in the adoption of new therapies and interventions that target specific symptoms and address the individual needs of patients. Additionally, there is a growing preference for non-invasive and non-pharmacological approaches, such as cognitive-behavioral therapy and psychosocial interventions, which offer a holistic approach to managing psychotic disorders.Trends in the market indicate a shift towards early intervention and preventive strategies. There is a growing recognition of the importance of early detection and treatment in improving outcomes for patients with psychotic disorders. As a result, healthcare providers in Benelux are investing in screening programs and early intervention services to identify and treat individuals at risk of developing psychosis. This proactive approach not only improves patient outcomes but also reduces the burden on healthcare systems by preventing the progression of psychotic disorders and the associated healthcare costs.Local special circumstances in Benelux further contribute to the development of the Psychotic Disorders market. The region has a well-established healthcare infrastructure and a strong focus on mental health services. There is a high level of awareness and acceptance of mental health issues, which has led to increased access to care and reduced stigma surrounding psychotic disorders. Additionally, the presence of leading research institutions and academic centers in Benelux fosters collaboration and innovation in the field of psychiatric research, driving advancements in treatment options and therapies.Underlying macroeconomic factors also play a role in the growth of the Psychotic Disorders market in Benelux. The region has a stable economy and a high level of healthcare expenditure, allowing for investment in mental health services and the development of new treatments. Furthermore, the aging population in Benelux is expected to increase the demand for mental health services, including those related to psychotic disorders. This demographic shift, coupled with the rising prevalence of mental health disorders globally, creates opportunities for market growth in the region.In conclusion, the Psychotic Disorders market in Benelux is developing due to customer preferences for innovative and personalized care, trends towards early intervention and preventive strategies, local special circumstances that support mental health services, and underlying macroeconomic factors such as a stable economy and an aging population. These factors contribute to the growth and advancement of the Psychotic Disorders market in Benelux, offering new opportunities for healthcare providers, researchers, and patients alike.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.